ATE516853T1 - Zyklische peptid-cxcr4-antagonisten - Google Patents

Zyklische peptid-cxcr4-antagonisten

Info

Publication number
ATE516853T1
ATE516853T1 AT08769524T AT08769524T ATE516853T1 AT E516853 T1 ATE516853 T1 AT E516853T1 AT 08769524 T AT08769524 T AT 08769524T AT 08769524 T AT08769524 T AT 08769524T AT E516853 T1 ATE516853 T1 AT E516853T1
Authority
AT
Austria
Prior art keywords
cyclic peptide
cxcr4 antagonists
peptide cxcr4
antagonists
cyclic
Prior art date
Application number
AT08769524T
Other languages
English (en)
Inventor
Wayne Kohn
Sheng-Bin Peng
Liang Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE516853(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE516853T1 publication Critical patent/ATE516853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT08769524T 2007-05-30 2008-05-20 Zyklische peptid-cxcr4-antagonisten ATE516853T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31
PCT/US2008/064177 WO2008150689A1 (en) 2007-05-30 2008-05-20 Cyclic peptide cxcr4 antagonists

Publications (1)

Publication Number Publication Date
ATE516853T1 true ATE516853T1 (de) 2011-08-15

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08769524T ATE516853T1 (de) 2007-05-30 2008-05-20 Zyklische peptid-cxcr4-antagonisten

Country Status (32)

Country Link
US (3) US7691813B2 (de)
EP (2) EP2377579A1 (de)
JP (1) JP5358564B2 (de)
KR (2) KR101169846B1 (de)
CN (1) CN101678213B (de)
AR (1) AR066648A1 (de)
AT (1) ATE516853T1 (de)
AU (1) AU2008260326B2 (de)
BR (1) BRPI0812134A2 (de)
CA (1) CA2688574C (de)
CL (1) CL2008001467A1 (de)
CO (1) CO6241137A2 (de)
CR (1) CR11105A (de)
CY (1) CY1111815T1 (de)
DK (1) DK2160221T3 (de)
DO (1) DOP2009000270A (de)
EA (1) EA017716B1 (de)
GT (1) GT200900304A (de)
HR (1) HRP20110551T1 (de)
IL (1) IL201685A (de)
JO (1) JO2776B1 (de)
MA (1) MA31666B1 (de)
MX (1) MX2009012952A (de)
MY (1) MY149432A (de)
NZ (1) NZ580849A (de)
PE (1) PE20090299A1 (de)
PL (1) PL2160221T3 (de)
PT (1) PT2160221E (de)
TN (1) TN2009000496A1 (de)
TW (1) TWI423987B (de)
WO (1) WO2008150689A1 (de)
ZA (1) ZA200908345B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) * 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
WO2012118124A1 (ja) * 2011-03-01 2012-09-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
BR112013031575B1 (pt) * 2011-06-07 2021-03-16 Polyphor Ag Composto peptídico ciclado de estrutura principal, composição farmacêutica, uso de um composto, e, processo para a manufatura de um composto
WO2013044500A1 (zh) * 2011-09-30 2013-04-04 Cheng Yun 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (de) 2014-07-31 2016-02-03 Greif International Holding BV. Mehrschichtmaterial, Brandschutzmatte mit diesem Mehrschichtmaterial sowie Transport- und Lagerbehälteranordnung mit dieser Brandschutzmatte
DK3050574T3 (da) 2015-01-28 2020-01-20 Univ Bordeaux Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
CA3032885C (en) * 2016-09-06 2023-06-20 Mainline Biosciences Cxcr4 antagonists and methods of use
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
US11123437B2 (en) * 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
KR20230145543A (ko) * 2017-09-05 2023-10-17 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
EA202190755A1 (ru) 2018-09-12 2021-06-11 Технише Универзитет Мюнхен Агенты для терапии и диагностики рака
CN119661653A (zh) 2018-09-12 2025-03-21 慕尼黑工业大学 具有降低的物种选择性的cxcr4靶向诊断和治疗剂
EP3956346A4 (de) * 2019-04-18 2023-01-18 Provincial Health Services Authority Neuartige radiomarkierte gegen cxcr4 gerichtete verbindungen zur diagnose und therapie
WO2021150258A1 (en) * 2020-01-26 2021-07-29 Mainline Biosciences Llc Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
WO2022082312A1 (en) * 2020-10-21 2022-04-28 Provincial Health Services Authority Novel cxcr4-targeting compounds
CN116615411A (zh) * 2020-12-25 2023-08-18 中外制药株式会社 包含n-取代氨基酸残基的肽化合物的制造方法
WO2022138891A1 (ja) * 2020-12-25 2022-06-30 中外製薬株式会社 Ｎ－置換－アミノ酸残基を含むペプチド化合物の製造方法
EP4043041A1 (de) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-liganden zur diagnostischen und therapeutischen verwendung und ihre vorläufer
EP4511384A4 (de) * 2022-04-20 2026-07-29 Provincial Health Services Authority Auf cxcr4 abzielende verbindungen und verfahren zur herstellung und verwendung davon
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用
WO2025218761A1 (zh) * 2024-04-17 2025-10-23 晶核生物医药科技(上海)有限公司 环状肽类化合物、其药物组合物及其应用
WO2026158397A1 (zh) * 2025-01-24 2026-07-30 域钛医疗科技(上海)有限公司 一种环肽化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
WO2007096662A2 (en) * 2006-02-27 2007-08-30 Technische Universität München Cancer imaging and treatment

Also Published As

Publication number Publication date
USRE42274E1 (en) 2011-04-05
NZ580849A (en) 2012-03-30
WO2008150689A1 (en) 2008-12-11
PE20090299A1 (es) 2009-03-19
MY149432A (en) 2013-08-30
AU2008260326B2 (en) 2011-07-21
AU2008260326A1 (en) 2008-12-11
CN101678213B (zh) 2013-11-06
EP2160221A1 (de) 2010-03-10
IL201685A (en) 2015-04-30
US7691813B2 (en) 2010-04-06
CA2688574A1 (en) 2008-12-11
EA017716B1 (ru) 2013-02-28
DOP2009000270A (es) 2010-01-15
US20100130409A1 (en) 2010-05-27
JP2010529957A (ja) 2010-09-02
PL2160221T3 (pl) 2011-12-30
HRP20110551T1 (hr) 2011-09-30
KR101169846B1 (ko) 2012-08-01
BRPI0812134A2 (pt) 2014-11-18
CN101678213A (zh) 2010-03-24
CO6241137A2 (es) 2011-01-20
JP5358564B2 (ja) 2013-12-04
CR11105A (es) 2010-04-12
EA200971129A1 (ru) 2010-04-30
AR066648A1 (es) 2009-09-02
JO2776B1 (en) 2014-03-15
KR20100003737A (ko) 2010-01-11
TN2009000496A1 (en) 2011-03-31
CA2688574C (en) 2014-02-18
IL201685A0 (en) 2010-05-31
MX2009012952A (es) 2009-12-11
GT200900304A (es) 2011-11-09
PT2160221E (pt) 2011-09-12
CY1111815T1 (el) 2015-10-07
TWI423987B (zh) 2014-01-21
DK2160221T3 (da) 2011-09-19
KR101319740B1 (ko) 2013-10-17
TW200902556A (en) 2009-01-16
EP2160221B1 (de) 2011-07-20
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
CL2008001467A1 (es) 2008-12-05
US20080300177A1 (en) 2008-12-04
HK1141474A1 (en) 2010-11-12
EP2377579A1 (de) 2011-10-19
MA31666B1 (fr) 2010-09-01

Similar Documents

Publication Publication Date Title
DK2160221T3 (da) Cykliske peptid-CXCR4-antagonister
HUS2200025I1 (hu) C5AR antagonisták
PL2252628T3 (pl) Koniugaty antagonistów peptydowych analogu bombezyny
HRP20151108T1 (xx) Antagonisti nogo-receptora
PL2465864T3 (pl) Szczepionki z peptydem pochodzącym z Eph4
BRPI0911743A2 (pt) "peptídeo"
DK3115370T3 (da) Biologisk aktive peptider
DK2443104T3 (da) Disubstituerede phthalazin-hedgehog-sti-antagonister
BRPI0810203A2 (pt) Compostos peptídeos cíclicos.
ZA201000776B (en) Cyclic depsipeptides
EP2236266A4 (de) Injektor
BR112012003701A2 (pt) "novos antagonistas de quinolina-hepcidina"
DK2364185T3 (da) Disubstituerede phthalazin-hedgehog-pathway-antagonister
BRPI0817835A2 (pt) Antagonistas cgrp
DK2799428T3 (da) Glucagon-antagonister
BRPI1010661A2 (pt) peptídeo
EP2197448A4 (de) Dosierplan
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
DE502007002482D1 (de) Injektor
DE502008002789D1 (de) Hochdruckreinigungsgerät
EP2280988A4 (de) Angiogenes peptid
DK2257534T3 (da) 3-aminoalkyl-1,4-diazepan-2-on-melanocortin-5-receptorantagonister
BRPI0907519A2 (pt) Antagonistas farmacoforos-pde4-muscarínicos duais
EP2370100A4 (de) Peptidhilfsstoffe
EP2195338A4 (de) N-terminal modifiziertes interferon-alpha

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2160221

Country of ref document: EP